Countries
Healthcare treats disease. Life care is about protecting health, every day, across a lifetime.
At Remidio, we believe eyesight is more than vision: it is a window into whole-body health and wellness. Our pioneering oculomics platform harnesses AI and innovative imaging to democratize health screening—so every eye exam can protect lives.
Healthcare today fails millions because early, continuous, and non-invasive signals for timely risk triage are missing. As a result, complications from diabetes, cardiovascular disease, kidney disorders, and other systemic conditions are detected too late
The eye we believe fixes that
Millions are left behind by traditional, reactive healthcare: vision loss and severe complications from diabetes, kidney, and heart disease, simply because screening arrives too late or care is fragmented.
Remidio harnesses AI-powered imaging and foundational vision models to use the eye as a scalable access point for holistic health monitoring—making proactive, preventive care affordable, mobile, and accessible across India, Southeast Asia, Africa, underserved regions in the US, and beyond
With Remidio, oculomics for the Next Billion becomes possible—affordable, mobile, and cloud-light screening tailored for India, Southeast Asia, Africa, and underserved regions in the US.
Every eye exam now has the power to protect both sight and life.
We empower every care provider to use the eye as a powerful, non-invasive “access point” for holistic health monitoring and early disease prevention.
.jpg)
Oculomics represents a fundamental shift in healthcare—from reacting to disease, to predicting and preventing it.
Oculomics is revolutionizing healthcare—shifting the focus from reacting to overt disease, to proactive and predictive screening.
The retina is the most information-dense, non-invasive health sensor in the human body. Remidio’s pioneering oculomics platform transforms routine eye exams into powerful life-care signals—enabling early, predictive, and population-scale health screening.
Routine eye scans, powered by Remidio’s Vision Foundational Models and simple-to-use imaging devices, converge with broader health monitoring—blurring the boundaries between ophthalmology, optometry, and primary care.
Routine eye scans, powered by Remidio’s AI, are converging with broader health monitoring, blurring the boundaries between ophthalmology, optometry, and primary care so systemic diseases can be tracked non-invasively.
No longer limited to privileged health systems, oculomics is now a practical pathway to early detection of diabetes, cardiovascular risk, chronic kidney disease, liver disease, anemia, pulmonary embolism, pre-eclampsia, neurodegeneration, and even biological aging—from a single eye exam.
No longer just for privileged health systems, oculomics is now a practical path to early detection of diabetes, cardiovascular risk, kidney disorders, liver disease, anemia, PE, and more, from a single eye exam.
Remidio’s patented, smartphone-enabled imaging devices deliver high-quality retinal images in any setting—urban clinics, rural outreach programs, public health centers, or even patients’ homes.
With On-the-Edge AI, all analysis and reporting happen instantly and offline, with no dependence on cloud GPUs or connectivity—ensuring patient privacy and rapid results.
Our evolving AI portfolio extends beyond blinding eye diseases such as DR, AMD, and Glaucoma to systemic disease risk triaging—including CVD, CKD, liver fibrosis, anemia, and pre-eclampsia—deployable with minimal training in non-specialist settings.
This bridges specialty medicine and primary care, enabling health systems to shift from episodic care to continuous risk intelligence, while making health screening accessible and convenient for patient
Certifications:
Oculomics for the Next Billion works across care silos, allowing primary care, optometry, and ophthalmology teams to collaborate on predictive screening, early triage, and streamlined referrals.
Routine eye exams now become part of general health screening, helping providers act earlier and prevent costly, late-stage complications.
Remidio’s multi-modal platform captures critical retinal, optic nerve, and anterior eye biomarkers, screening for multiple diseases in just minutes.Our roadmap includes validated, lightweight deployment for anemia, liver fibrosis, pulmonary embolism, and beyond.
.webp)
Remidio’s oculomics vision is to bring predictive, preventive health to populations who need it most.
Our mobile, affordable, and locally validated platform is being adopted in nationwide health programs, government missions, and public-private pilots across 40+ countries.
Routine eye scans can now be part of general health screening, and Remidio is building the data moat and partnerships to make this scale.
Join Remidio’s movement to make proactive, predictive health possible for everyone—where every eye exam is a gateway to saving sight and lives.